Process Development and Scale Up of a Glycine Antagonist

Adam Banks, Gary F. Breen, Darren Caine, John Carey, Christopher Drake, Michael A. Forth, Asa Gladwin, Simone Guelfi, Jerome F. Hayes, Paolo Maragni,

Organic Process Research & Development · 2009 · 27 citations · 21 references

Concepts

Abstract

A synthetic route amenable to large-scale synthesis of the glycine antagonist (2 R,4 E )-7-chloro-4-(2-oxo-1-phenyl-pyyrrolidin-3-ylidene)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid, (2 R,3 R,4 R,5 S )-6-(methylamino)hexane-1,2,3,4,5-penta-ol 12 is presented. The route consists of four stages of chemistry. Stage 1 starts from 5-chloro-2-iodoaniline hydrochloride and is a three-step telescoped stage consisting of an imine formation with ethyl glyoxalate, Mannich reaction using vinyloxytrimethylsilane, and subsequent Wittig reaction with (2-oxo-1-phenyl-3-pyrrolidinyl)triphenylphosphonium bromide. The stage 1 product (4 E )-2[(5-chloro-2-iodophenyl)amino]-4-(2-oxo-1-phenyl-pyrrolidin-3-ylidene)butanoic acid ethyl ester 17 is subjected to an enzyme-catalysed kinetic resolution to prepare the single (2 R )-enantiomer 19 as the ethyl ester. Stage 3 is the intramolecular Heck reaction to yield (2 R,4 E )-7-chloro-4-(2-oxo-1-phenyl-pyrrolidin-3-ylidene)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid ethyl ester 31 . The final stage is ester saponification and meglumine salt formation to afford the drug candidate molecule 12 . In total, more than 300 kg of target 12 was produced with a purity >99.9%. Aspects of route selection as well as elements of process understanding and control are discussed.

References

21